Loading page…

Report overview

The report describes a double materiality assessment that includes Hanmi Pharmaceutical and its consolidated subsidiaries, Hanmi Fine Chemical and Beijing Hanmi Pharmaceutical. It sets out a Scope 1 and 2 emissions roadmap with a 30% reduction target by 2030 and Net Zero by 2040. In 2025, the company also carried out six cleanup activities around its Pyeongtaek industrial complex, business sites, and parks.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
CDP score

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Scope 2 emissions
Scope 3 emissions
Energy consumption
Renewable energy
Water consumption
Waste
Employees
Women on the board
Net zero target

Materiality

Assessment
Basis
Matrix

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services

ESG Report

Report overview

Document

Standards & Assurance

Standards

Commitments

Ratings

Assurance

ESG & Materiality

ESG data

Materiality

Build your research dataset.

ESG Report

Report overview

Document

Standards & Assurance

Standards

Commitments

Ratings

Assurance

ESG & Materiality

ESG data

Materiality

Build your research dataset.